We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Lissette
Sanchez-Aranguren
sanchel2@aston.ac.uk
Kady
Hutton
ras@uhb.nhs.uk
Caroline
Kardeby
caroline.kardeby@aston.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedExtrapyramidal and movement disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Today, more than 10 million people worldwide live with Parkinson’s; a brain disorder that affects the nerve cells of the body. People who have Parkinson's typically have symptoms that include an unwanted tremor which is worse at rest, as well as muscle stiffness and slowness of movement. However, there are also a number of invisible symptoms such as dementia that affects the memory. Both movement- and memory- related symptoms are caused by the death of nerve cells in the deep parts of the brain, and each individual may experience them differently.
What is less commonly known is that those suffering with Parkinson's also experience a higher risk of suffering blood clots in their legs or brain, which can have profound life altering changes, such as strokes. What causes the increased risk for blood clots is still unknown. However, we do know is that blood clots increase the risk for the Parkinson's symptoms to get worse and they also increase the risk of death.
In this study we will collect blood samples from patients with Parkinson’s and healthy volunteers and compare their blood’s ability to form clots and the levels of inflammation.
From this study we want to understand if it would be useful to conduct future studies where we evaluate the beneficial effects of giving medicines to the patients that prevent blood clots from happening. We also want to understand which, if any, medicines might be useful to prevent the symptoms from getting worse. We hope that our results will give new understanding of how Parkinson’s occurs, gets progressively worse, and why there is an increased risk for blood clots. Through gaining this new knowledge, we want our results to contribute to new potential treatments and ways to identify who might be at risk of blood clots and stroke.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
Exclusion criteria for participants with Parkinson's: • Diagnosis of diseases with known platelets and coagulation defects such as Bernard-Soulier syndrome, Glanzmann’s thrombasthenia, Hemophilia, or von Willebrand disease. • Participant must have not used any non-steroid anti-inflammatory drugs or platelet inhibitors like aspirin and clopidogrel in the past 14 days before the blood sampling on the day of enrolment to the study. Exclusion criteria for healthy volunteers: • Diagnosis of diseases with known platelets and coagulation defects such as Bernard-Soulier syndrome, Glanzmann’s thrombasthenia, Hemophilia, or von Willebrand disease. • Participant must have not used any non-steroid anti-inflammatory drugs or platelet inhibitors like aspirin and clopidogrel in the past 14 days before the blood sampling on the day of enrolment to the study. • Participants may not be diagnosed with a neurodegenerative disease, have other chronic conditions that are not under control, or have suffered a recent vascular event (less than 1 year ago at time of enrolment). • Participants may not be diagnosed with diabetes or rheumatoid arthritis.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Kady
Hutton
ras@uhb.nhs.uk
Caroline
Kardeby
caroline.kardeby@aston.ac.uk
Lissette
Sanchez-Aranguren
sanchel2@aston.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Aston University and funded by BRITISH HEART FOUNDATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 58225
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
